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Although the prevalence of species of the genus Acinetobacter
other than Acinetobacter baumannii has seemingly increased as
a cause of nosocomial infections in different geographical
areas [1], the latter species continues to be the most preva-
lent in hospital settings. Several characteristics of this micro-
organism should be highlighted: (i) the intrinsic resistance
associated with the interplay between decreased outer mem-
brane permeability and constitutive expression of some
efﬂux pumps; (ii) the acquisition of genetic elements such as
resistance islands, which may carry up to 45 resistance genes
or insertion sequence elements—these latter elements can
be inserted upstream from some chromosomal genes and
can contribute to the expression of these genes, such as
blaADC or blaOXA-51, encoding a chromosomal cephalosporin-
ase and a carbapenemase, respectively, and in addition, muta-
tions in genes related to the overexpression of efﬂux pumps
(AdeABC and AdeIJK) can generate multiresistance, as these
efﬂux pumps normally have different substrates; and (iii) the
ability to survive in the environment, most likely associated
with bioﬁlm production, which can contribute to the acquisi-
tion of either mutations or genetic elements [2,3]. All the
above-mentioned features lead to the development of multi-
drug-resistant, extended-drug-resistant and pan-drug-resis-
tant A. baumannii strains. Therefore, not many alternatives
are available to treat the infections caused by pan-resistant
A. baumannii strains. The drugs currently available, which
show a lower percentage of resistant clinical isolates, are
colistin and tigecycline. Colistin has been used in several
studies to treat infections caused by multidrug-resistant
A. baumannii, with suboptimal results. To improve its efﬁcacy,
recent pharmacokinetic/pharmacodynamic data have led to
the suggestion that the colistin dosage should be optimized
with an initial loading dose, to enable therapeutic concentra-
tions to be reached more rapidly [4]. Tigecycline has shown
good in vitro activity against A. baumannii; however, few data,
none of them deﬁnitive, have been reported from non-
comparative studies concerning its efﬁcacy in A. baumannii
infections. Moreover, rapid appearance of resistance has
occurred during the treatment, most likely associated with
the overexpression of AdeABC and/or other efﬂux pumps.
Among the possible combination therapies for the treatment
of multidrug-resistant A. baumannii infections, rifampin plus
colistin has been evaluated in ventilator-associated pneumo-
nia and bacteraemia. Once more, the results have been dis-
cordant, and it may be stressed that a high dose of rifampin
must be used; moreover, to avoid the appearance of rifampin
resistance during the treatment, it is necessary to ensure, in
the case of empirical therapy, that the drug combined with
rifampin is active against the A. baumannii strains causing
infections in a particular setting.
The problematic situation generated by A. baumannii has
not been reﬂected in the development of new antibacterial
agents against this microorganism. The last drugs developed,
such as doripenem, ceftobiprole and ceftalorine, do not
show activity against A. baumannii resistant to carbapenems
or cephalosporins.
Taking into consideration all the above, it is evident that
we desperately need new approaches, including new antibac-
terial agents, to control A. baumannii infections. The new
drugs could be aimed at: (i) essential proteins or processes
for the bacteria that have not been used so far; and (ii) pro-
cesses such as antibiotic resistance and bacterial virulence.
Targeting antibiotic resistance is an attractive approach,
because it would help to reduce antibiotic resistance itself,
and it would allow the recovery of antibiotics to which bac-
teria have already become resistant. In this sense, the devel-
opment of efﬂux pumps or b-lactamase inhibitors should be
noted. Studies on drugs targeting the mechanisms that allow
bacteria to produce infections are also underway [5]. Antimi-
crobial peptides have attracted increasing interest as poten-
tial new antimicrobial agents. Some of these antimicrobial
agents show good in vitro activity, even against colistin-resis-
tant A. baumannii. Modiﬁcations to the basic structure of
these peptides can be performed to improve their pharma-
cokinetic/pharmacodynamic features. Additionally, non-anti-
microbial approaches need to be addressed. Recently, in a
murine model of disseminated sepsis, active and passive
immunization with an inactivated whole cell vaccine was
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effective in preventing infection by A. baumannii [6]. Finally, it
must be stressed that there is an urgent need to reinforce
research on the epidemiology of resistance, surveillance, and
the proven measures to control hospital infections.
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